Fig. 8

Transplantation of CD11b/LIF transgenic BMCs reduces the numbers of FAPs in dystrophic muscle but does not affect phenotype. a QPCR analysis shows that TA muscles from LIF BMT/mdx recipients have reduced Pdgfra gene expression. N = 7 or 8 for WT BMT/mdx and LIF BMT/mdx data sets, respectively, * indicates significantly different from WT BMT/mdx recipients at P < 0.05. P-values based on two-tailed t-test. For all histograms in the figure, the bars indicate mean ± sem. b To quantify the number of FAPs, muscle sections were co-labeled with antibodies to PDGFRα (red) and CD31, CD45 (green). Arrowheads indicate FAPs (CD31-CD45-PDGFRα+). Bar = 50 μm. c Fewer FAPs (CD31-CD45-PDGFRα+) in TA cross-sections of LIF BMT/mdx recipients compared to WT BMT/mdx recipients. N = 5 for each data set. d There was no detectible change in phenotype of PDGFRα+ cells assayed for co-expression of the fibrogenic marker HSP47. e FACS plots demonstrating strategy for sorting FAPs (Hoechst + CD11b-CD31-CD45-PDGFRα+). Fibroblasts derived from FAPs were stimulated with LIF (10 ng/ml) and/or TGFβ1 (10 ng/ml) for 3 h (f–h) or 3 days (i–k) and assayed by QPCR for Ctgf (f, i), Fn1 (g, j), and Col1a1 (h, k). N = 4 technical replicates for each data set. Significant findings were verified with biological replicates of cells sorted from independent donors. * Indicates significantly different from control cultures, # indicates significantly different from TGFβ1 treated cultures, and Φ indicates significantly different from LIF-treated cultures at P < 0.05. P-values based on ANOVA with Tukey’s multiple comparison test. Source data are provided as a Source Data file